Featured Research

from universities, journals, and other organizations

Are research participants safe enough?

Date:
April 26, 2010
Source:
Canadian Medical Association Journal
Summary:
Rules and regulations are threatening academic clinical trials in Canada which contribute to the public good, states an editorial.

Every year, millions of patients worldwide participate in randomized clinical trials hoping to benefit from an experimental treatment or potentially help someone else with the same condition.

However, rules and regulations are becoming a menace to academic clinical trials where resources are limited and risks may be much less than those associated with new experimental drugs.

"There is no question that research participants need protection," write Paul Hιbert, Editor-in-Chief, CMAJ, and coauthors. "But regulations have grown so burdensome that they are overwhelming the very things they are meant to support and safeguard. Consequently, clinical research has been substantially decreased among industrialized countries."

International bodies, regulatory authorities, the academic community and major granting agencies need to work together to develop and adopt proper, study-specific standards instead of having ineffective monitoring of all clinical research.

The authors conclude that without significant changes, our academic research enterprise and eventually even commercial trials will be immobilized by increasing bureaucracy and spiraling costs.


Story Source:

The above story is based on materials provided by Canadian Medical Association Journal. Note: Materials may be edited for content and length.


Journal Reference:

  1. Paul C Hιbert and Dean A Fergusson. Are we keeping research participants safe enough? CMAJ, 2010; DOI: 10.1503/cmaj.100404

Cite This Page:

Canadian Medical Association Journal. "Are research participants safe enough?." ScienceDaily. ScienceDaily, 26 April 2010. <www.sciencedaily.com/releases/2010/04/100426131422.htm>.
Canadian Medical Association Journal. (2010, April 26). Are research participants safe enough?. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/04/100426131422.htm
Canadian Medical Association Journal. "Are research participants safe enough?." ScienceDaily. www.sciencedaily.com/releases/2010/04/100426131422.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins